vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $169.0K, roughly 3542.4× Aligos Therapeutics, Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -11763.9%, a 11804.8% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -72.1%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ALGS vs EXEL — Head-to-Head
Income Statement — Q4 2025 vs Q4 2026
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $598.7M |
| Net Profit | $-19.9M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | -12907.7% | 39.3% |
| Net Margin | -11763.9% | 40.8% |
| Revenue YoY | -72.1% | 5.6% |
| Net Profit YoY | 75.8% | 74.8% |
| EPS (diluted) | $4.23 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $598.7M | ||
| Q4 25 | $169.0K | $597.8M | ||
| Q3 25 | $741.0K | $568.3M | ||
| Q2 25 | $965.0K | $555.4M | ||
| Q1 25 | $311.0K | $566.8M | ||
| Q4 24 | $606.0K | — | ||
| Q3 24 | $1.3M | $539.5M | ||
| Q2 24 | $1.1M | $637.2M |
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-19.9M | $193.6M | ||
| Q3 25 | $-31.5M | $184.8M | ||
| Q2 25 | $-15.9M | $159.6M | ||
| Q1 25 | $43.1M | $139.9M | ||
| Q4 24 | $-82.2M | — | ||
| Q3 24 | $-19.3M | $118.0M | ||
| Q2 24 | $5.1M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% |
| Q1 26 | — | 39.3% | ||
| Q4 25 | -12907.7% | 39.6% | ||
| Q3 25 | -3827.4% | 37.6% | ||
| Q2 25 | -1924.0% | 33.6% | ||
| Q1 25 | -6187.5% | 28.8% | ||
| Q4 24 | -3393.2% | — | ||
| Q3 24 | -1610.5% | 25.2% | ||
| Q2 24 | -2489.5% | 43.3% |
| Q1 26 | — | 40.8% | ||
| Q4 25 | -11763.9% | 32.4% | ||
| Q3 25 | -4256.0% | 32.5% | ||
| Q2 25 | -1643.8% | 28.7% | ||
| Q1 25 | 13854.7% | 24.7% | ||
| Q4 24 | -13556.1% | — | ||
| Q3 24 | -1540.7% | 21.9% | ||
| Q2 24 | 477.0% | 35.5% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $4.23 | $0.69 | ||
| Q3 25 | $-3.04 | $0.65 | ||
| Q2 25 | $-1.53 | $0.55 | ||
| Q1 25 | $-2.11 | $0.47 | ||
| Q4 24 | $-13.10 | — | ||
| Q3 24 | $-3.07 | $0.40 | ||
| Q2 24 | $0.81 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $2.2B |
| Total Assets | $88.5M | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.1B | ||
| Q4 25 | $77.8M | $988.5M | ||
| Q3 25 | $99.1M | $791.1M | ||
| Q2 25 | $122.9M | $1.0B | ||
| Q1 25 | $137.9M | $1.1B | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | $1.2B | ||
| Q2 24 | $94.5M | $1.0B |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $53.5M | $2.2B | ||
| Q3 25 | $71.8M | $2.0B | ||
| Q2 25 | $101.9M | $2.1B | ||
| Q1 25 | $116.4M | $2.2B | ||
| Q4 24 | $-29.0M | — | ||
| Q3 24 | $50.1M | $2.3B | ||
| Q2 24 | $67.2M | $2.1B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $88.5M | $2.8B | ||
| Q3 25 | $109.8M | $2.7B | ||
| Q2 25 | $134.7M | $2.8B | ||
| Q1 25 | $150.7M | $2.9B | ||
| Q4 24 | $70.1M | — | ||
| Q3 24 | $88.4M | $3.0B | ||
| Q2 24 | $108.8M | $2.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-21.7M | $333.5M |
| Free Cash FlowOCF − Capex | — | $332.4M |
| FCF MarginFCF / Revenue | — | 55.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | — | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $-21.7M | $290.3M | ||
| Q3 25 | $-24.3M | $49.0M | ||
| Q2 25 | $-15.5M | $211.4M | ||
| Q1 25 | $-20.9M | $240.3M | ||
| Q4 24 | $-18.4M | — | ||
| Q3 24 | $-20.1M | $271.3M | ||
| Q2 24 | $-19.5M | $119.5M |
| Q1 26 | — | $332.4M | ||
| Q4 25 | — | $288.8M | ||
| Q3 25 | — | $46.2M | ||
| Q2 25 | — | $208.5M | ||
| Q1 25 | — | $236.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $263.1M | ||
| Q2 24 | — | $113.0M |
| Q1 26 | — | 55.5% | ||
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 37.5% | ||
| Q1 25 | — | 41.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 17.7% |
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | -0.49× | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | -3.85× | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
